, NURS 5334 / NURS5334: Advanced
Pharmacology – Exam 2 Questions and
Correct Answers with Rationale 2026/2027
Question 1
Which pharmacokinetic parameter describes the fraction of an
administered dose of a drug that reaches the systemic circulation in an
unchanged form?
A. Volume of distribution
B. Bioavailability
C. Clearance
D. Half-life
Correct Answer: B
Rationale: Bioavailability measures the rate and extent to which an
active drug ingredient is absorbed and becomes available at the site of
action or systemic circulation.
Question 2
What is the primary mechanism by which phase II drug-metabolizing
reactions alter xenobiotics?
A. Oxidation via the cytochrome P450 enzyme system
B. Reduction of polar functional groups
C. Conjugation with endogenous polar molecules to enhance water
solubility and excretion
,D. Hydrolysis of ester bonds in the gastrointestinal tract
Correct Answer: C
Rationale: Phase II reactions involve conjugation (e.g., glucuronidation,
sulfation, acetylation) with polar endogenous substances, converting
lipid-soluble drugs into hydrophilic compounds easily cleared by the
kidneys or bile.
Question 3
Which cytochrome P450 enzyme is responsible for the metabolism of
the largest percentage of clinically prescribed drugs?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4
Correct Answer: D
Rationale: CYP3A4 is the most abundant CYP450 enzyme in the liver
and intestine, metabolizing roughly half of all marketed medications,
which makes it a frequent site for drug-drug interactions.
Question 4
What term defines a drug that binds to a receptor, activates it, but
produces a submaximal efficacy compared to a full agonist regardless of
concentration?
A. Competitive antagonist
B. Partial agonist
, C. Inverse agonist
D. Noncompetitive antagonist
Correct Answer: B
Rationale: Partial agonists bind to receptors and stimulate a response,
but their intrinsic efficacy is lower than that of full agonists, allowing
them to act as antagonists in the presence of a full agonist.
Question 5
What is the primary effect of chronic administration of a CYP450
enzyme inducer on a co-administered substrate drug?
A. Increased plasma concentrations and heightened toxicity
B. Decreased plasma concentrations and potential therapeutic failure
C. Immediate inhibition of renal excretion pathways
D. Irreversible covalent binding to plasma proteins
Correct Answer: B
Rationale: Enzyme inducers upregulate the synthesis of specific CYP
enzymes, accelerating the biotransformation and elimination of substrate
drugs, which lowers their blood levels and efficacy.
Question 6
Which phase of clinical trials involves testing a new drug in a small
group of healthy volunteers primarily to evaluate safety,
pharmacokinetics, and tolerability?
A. Phase I
B. Phase II
Pharmacology – Exam 2 Questions and
Correct Answers with Rationale 2026/2027
Question 1
Which pharmacokinetic parameter describes the fraction of an
administered dose of a drug that reaches the systemic circulation in an
unchanged form?
A. Volume of distribution
B. Bioavailability
C. Clearance
D. Half-life
Correct Answer: B
Rationale: Bioavailability measures the rate and extent to which an
active drug ingredient is absorbed and becomes available at the site of
action or systemic circulation.
Question 2
What is the primary mechanism by which phase II drug-metabolizing
reactions alter xenobiotics?
A. Oxidation via the cytochrome P450 enzyme system
B. Reduction of polar functional groups
C. Conjugation with endogenous polar molecules to enhance water
solubility and excretion
,D. Hydrolysis of ester bonds in the gastrointestinal tract
Correct Answer: C
Rationale: Phase II reactions involve conjugation (e.g., glucuronidation,
sulfation, acetylation) with polar endogenous substances, converting
lipid-soluble drugs into hydrophilic compounds easily cleared by the
kidneys or bile.
Question 3
Which cytochrome P450 enzyme is responsible for the metabolism of
the largest percentage of clinically prescribed drugs?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4
Correct Answer: D
Rationale: CYP3A4 is the most abundant CYP450 enzyme in the liver
and intestine, metabolizing roughly half of all marketed medications,
which makes it a frequent site for drug-drug interactions.
Question 4
What term defines a drug that binds to a receptor, activates it, but
produces a submaximal efficacy compared to a full agonist regardless of
concentration?
A. Competitive antagonist
B. Partial agonist
, C. Inverse agonist
D. Noncompetitive antagonist
Correct Answer: B
Rationale: Partial agonists bind to receptors and stimulate a response,
but their intrinsic efficacy is lower than that of full agonists, allowing
them to act as antagonists in the presence of a full agonist.
Question 5
What is the primary effect of chronic administration of a CYP450
enzyme inducer on a co-administered substrate drug?
A. Increased plasma concentrations and heightened toxicity
B. Decreased plasma concentrations and potential therapeutic failure
C. Immediate inhibition of renal excretion pathways
D. Irreversible covalent binding to plasma proteins
Correct Answer: B
Rationale: Enzyme inducers upregulate the synthesis of specific CYP
enzymes, accelerating the biotransformation and elimination of substrate
drugs, which lowers their blood levels and efficacy.
Question 6
Which phase of clinical trials involves testing a new drug in a small
group of healthy volunteers primarily to evaluate safety,
pharmacokinetics, and tolerability?
A. Phase I
B. Phase II
